STOCK TITAN

Athira Pharma, Inc. - ATHA STOCK NEWS

Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.

Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.

The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.

Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.

Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.

Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.

For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) urges shareholders to vote ‘FOR’ its independent director nominees at the Annual Meeting on May 19, 2022. The company emphasizes the importance of using the WHITE proxy card over any blue cards from Richard Kayne. Leading proxy advisors, ISS and Glass Lewis, recommend supporting Athira's nominees, highlighting the board’s effectiveness and strategic focus on advancing fosgonimeton (ATH-1017) for neurological diseases. Results from the Phase 2 ACT-AD study are anticipated by the end of Q2 2022, amidst ongoing efforts to enhance shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.46%
Tags
none
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced an extension of its open-label treatment duration for the Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton, increasing from 6 to 18 months. This decision follows a review by the independent Data and Safety Monitoring Board (DSMB). Participants who completed the initial trials can opt for continued treatment, reflecting strong interest from both investigators and patients. The LIFT-AD trial's topline results are expected in H1 2023, while ACT-AD results are targeted for Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
-
Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA) encourages shareholders to vote 'FOR' its independent director nominees—Joseph Edelman, John M. Fluke, Jr., and Grant Pickering—using the WHITE proxy card ahead of the annual meeting on May 19, 2022. The company highlights its progress in clinical trials, particularly for its lead candidate, fosgonimeton (ATH-1017), with topline results expected from the Phase 2 ACT-AD study by Q2 2022, and full enrollment of the LIFT-AD Phase 3 study targeted for Q3 2022. The board expresses confidence in its leadership amidst a proxy contest led by Richard Kayne, urging shareholders to support its current board to maintain momentum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
none
Rhea-AI Summary

Richard A. Kayne, owning 4.8% of Athira Pharma, urges the Board to seek a new CEO with clinical experience to enhance the success rate of ongoing trials for ATH-1017. He proposed Dr. Ronald Krall, a former Chief Medical Officer at GlaxoSmithKline, citing his extensive experience overseeing 20 FDA approvals. Dr. Krall expresses readiness to lead Athira and improve the management of critical ACT-AD and LIFT-AD trials, emphasizing the need for experienced oversight in this pivotal phase for the company’s drug candidate.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
Rhea-AI Summary

Ric Kayne, a significant shareholder of Athira Pharma (NASDAQ: ATHA), has criticized the current Board of Directors for poor decision-making that has led to substantial shareholder value destruction. Highlighting recent missteps, including the termination of former CEO Dr. Leen Kawas and the promotion of inexperienced Dr. Mark Litton, Kayne calls for immediate changes to restore Board credibility. He emphasizes the urgency to elect new directors, including himself and George Bickerstaff, to safeguard the company’s future and enhance its Alzheimer’s treatment, ATH-1017.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
none
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) is urging shareholders to vote for its independent director nominees ahead of its Annual Meeting. The company highlights its strategic position as it prepares for pivotal clinical data, including topline results from the Phase 2 ACT-AD study by Q2 2022 and full enrollment of the LIFT-AD Phase 3 study by Q3 2022. Athira emphasizes strong management with extensive biopharma experience and a robust board aimed at advancing its drug development strategies for neurodegenerative conditions. A proxy contest led by Richard Kayne is described as unnecessary and misaligned with shareholder interests.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
Rhea-AI Summary

Ric Kayne, who owns approximately 4.8% of Athira's common stock, has launched a campaign urging shareholders to vote for new directors to enhance oversight of clinical trials for ATH-1017. He criticizes the current Board for poor decision-making and governance failures, claiming it jeopardizes shareholder value and ATH-1017's potential. Kayne emphasizes the need for a capable Board with industry expertise to navigate ongoing clinical trials. He encourages shareholders to vote their BLUE proxy cards to ensure critical changes are made for long-term success.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
management
-
Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA) emphasizes the importance of shareholder support for its independent director nominees, Joseph Edelman, John M. Fluke, Jr., and Grant Pickering, urging votes on the WHITE proxy card. The company highlights recent additions to its board, consisting of seven new members within three years, who bring valuable skills across clinical development, regulatory processes, and finance. Athira aims to advance its clinical trials, particularly for fosgonimeton, amidst a proxy contest that threatens to disrupt its progress. It calls for shareholders to protect the value of their investment by voting for its nominee directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary

Ric Kayne, a significant shareholder of Athira Pharma (NASDAQ: ATHA), filed a proxy statement urging shareholders to replace CEO Dr. Mark Litton with more qualified leadership. Kayne argues that under current management, the chances of success for ATH-1017, a treatment for Alzheimer's, are jeopardized. He cites a 30% drop in market capitalization since Litton's appointment and questions the board's decision-making. The upcoming shareholders' meeting on May 19, 2022, presents an opportunity for change, with Kayne and former Novartis CFO George Bickerstaff as nominees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
none
Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA) filed its definitive proxy statement with the SEC for the upcoming Annual Meeting on May 19, 2022, urging shareholders to vote for its director nominees on the WHITE proxy card. The company highlights effective execution against strategic priorities and anticipates topline results from the Phase 2 ACT-AD study by the end of Q2 2022. Athira is well-capitalized, positioned to meet clinical milestones, and emphasizes the expertise of its board nominees while opposing a disruptive proxy contest initiated by shareholder Richard A. Kayne.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none

FAQ

What is the current stock price of Athira Pharma (ATHA)?

The current stock price of Athira Pharma (ATHA) is $0.576 as of December 20, 2024.

What is the market cap of Athira Pharma (ATHA)?

The market cap of Athira Pharma (ATHA) is approximately 20.7M.

What is Athira Pharma, Inc.?

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.

What are Athira's lead compounds?

Athira's lead compounds include Fosgonimeton (ATH-1017) for Alzheimer's disease, ATH-1105 for ALS, and ATH-1020 for neurodegenerative disorders.

What is the focus of Athira's research?

Athira's research focuses on modulating the neurotrophic hepatocyte growth factor (HGF) system to treat neurodegenerative diseases.

When are the next significant milestones for Athira?

Athira expects to report topline data from its Phase 2/3 LIFT-AD trial for Fosgonimeton in Alzheimer’s disease in the second half of 2024 and to initiate first-in-human studies for ATH-1105 in 2024.

Who funds Athira's research?

Athira's research is funded by organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures.

What differentiates Athira's approach from other companies?

Athira differentiates itself by targeting the neurodegenerative process and developing cost-effective solutions that address the root causes of neurodegenerative diseases.

What is Fosgonimeton?

Fosgonimeton (ATH-1017) is Athira's lead compound, designed to enhance the neurotrophic HGF system and currently being tested for Alzheimer's disease.

What recent achievements has Athira reported?

Recent achievements include promising preclinical results for ATH-1105 in ALS models and the completion of Phase 2/3 LIFT-AD trial enrollment for Fosgonimeton in Alzheimer’s disease.

How does Athira contribute to the scientific community?

Athira regularly presents its research at major scientific conferences and publishes in peer-reviewed journals, contributing to the broader understanding of neurodegenerative diseases.

Where can I find more information about Athira Pharma?

More information about Athira Pharma, Inc. can be found on their official website at www.athira.com and their social media pages on Facebook, LinkedIn, X (formerly Twitter), and Instagram.

Athira Pharma, Inc.

Nasdaq:ATHA

ATHA Rankings

ATHA Stock Data

20.71M
31.97M
1.95%
62.14%
4.05%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BOTHELL